The identification of drug combinations as alternatives to single-agent therapeutics has traditionally been a slow, largely manual process. In the last 10 years, high-throughput screening platforms have been developed that enable routine screening of thousands of drug pairs in an in vitro setting. In this chapter, we describe the workflow involved in screening a single agent versus a library of mechanistically annotated, investigation, and approved drugs using a full dose-response matrix scheme using viability as the readout. We provide details of the automation required to run the screen and the informatics required to process data from screening robot and subsequent analysis and visualization of the datasets.
Drug combination screening Acoustic dispensing Automation Compound management Synergy
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
We would like to thank Lesley Mathews-Griner, John Keller, and Don Liu for their contributions to the development of the NCATS combination screening platform.
Borisy AA et al (2003) Systematic discovery of multicomponent therapeutics. Proc. Nat. Acad. Sci 100:7977–7982CrossRefGoogle Scholar
Lehár J et al (2007) Chemical combination effects predict connectivity in biological systems. Mol Sys Bio 3:80Google Scholar
Lehár J et al (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotech. 27:659–666CrossRefGoogle Scholar
Bansal M et al (2014) A community computational challenge to predict the activity of pairs of compounds. Nat. Biotech. 32:1213–1222CrossRefGoogle Scholar
Attene-Ramos M et al (2013) The Tox21 robotic platform for the assessment of environmental chemicals—from vision to reality. Drug Discov Today 18:716–723CrossRefGoogle Scholar
Yasgar A, Shinn P, Jadhav A et al (2008) Compound management for quantitative high-throughput screening. JALA 13:79–89PubMedGoogle Scholar
Hafner M et al (2016) Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Meth 13:521–527CrossRefGoogle Scholar
Heske CM et al (2017) Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma. Clin Cancer Res 23(23):7301–7311CrossRefGoogle Scholar
Malo N, Hanley J, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-throughput screening data analysis. Nat Biotech 24:167–175CrossRefGoogle Scholar
Zhang XD (2007) A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics 89:552–561CrossRefGoogle Scholar
Chen L et al (2016) mQC: a heuristic quality-control metric for high-throughput drug combination screening. Sci Rep 6:37741CrossRefGoogle Scholar
Borisy AA et al (2003) Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci 100:7977–7982CrossRefGoogle Scholar
Schindler M (2017) Theory of synergistic effects: hill-type response surfaces as ‘null-interaction’ models for mixtures. Theor Biol Med Model 14:15CrossRefGoogle Scholar
Cokol M et al (2011) Systematic exploration of synergistic drug pairs. Mol Syst Biol 7:544CrossRefGoogle Scholar